Profile: United Therapeutics Corp (UTHR.O)
21 Aug 2017
United Therapeutics Corporation, incorporated on June 26, 1996, is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies. The Company focuses its research and development efforts on pipeline programs, including RemoSynch (Implantable System for Remodulin), RemUnity, Tysuberprost, Unituxin, Aurora-GT, Orenitram, OreniPlus, OreniLeft and OreniCell.
Remodulin, Tyvaso and Orenitram are prostacyclin vasodilators. Intravenous Remodulin is delivered through a surgically implanted central venous catheter. Tyvaso is administered four times a day by inhaling up to nine breaths during each treatment session, which takes approximately three minutes. Tyvaso is required to be administered using Tyvaso Inhalation System, which consists of an ultra-sonic nebulizer that provides a dose of Tyvaso on a breath-by-breath basis. Orenitram is an extended-release, oral tablet form of treprostinil. Adcirca is a Phosphodiesterase Type 5 (PDE-5) inhibitor, the active pharmaceutical ingredient of which is tadalafil. The Company sells Remodulin, Tyvaso and Orenitram to specialty pharmaceutical distributors in the United States and to pharmaceutical distributors internationally.
The Company competes with GlaxoSmithKline PLC, Actelion, Bayer Schering Pharma AG, Gilead Sciences, Inc., Pfizer Inc., Nippon Shinyaku Co., Ltd., Arena Pharmaceuticals, Inc., SteadyMed Ltd. and Reata Pharmaceuticals, Inc.
United Therapeutics Corp
1040 SPRING ST
SILVER SPRING MD 20910
Company Web Links
- BRIEF-United Therapeutics Corp reports Q2 EPS non-GAAP $4.37
- BRIEF-United Therapeutics enters into agreement with Citibank relating to share repurchase program
- BRIEF-United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company
- BRIEF-United Therapeutics announces $250 mln share repurchase program
- BRIEF-United Therapeutics and 3D Systems announce bioprinting agreement